Chat with MASLD AI
Hi, I am MASLD AI.
Suggested Questions :
MASLD AI 07:06 AM
November 2025
In this insightful session, Alison Moe, PA-C, from Atlantic Gastroenterology Associates, a division of United Digestive, breaks down how to distinguish metabolic-associated steatotic liver disease (MASLD) from MetALD—the overlap of metabolic dysfunction and alcohol-related liver injury. Using a real-world case study, Alison highlights how small amounts of daily alcohol intake can significantly accelerate fibrosis in patients with metabolic risk factors like PCOS, hypertension, and dyslipidemia. She explains how to interpret FibroScan (kPa/CAP) results, evaluate PEth testing for alcohol exposure, and determine when therapies such as Resmetirom are appropriate. This discussion emphasizes practical strategies for counseling patients on alcohol cessation, lifestyle modification, and fibrosis monitoring, helping clinicians better identify and manage those at risk for advanced liver disease.
Related Webcast
Live From GHAPP National: Abnormal Liver Imaging: What's Next?
November 2025
In this high-yield session, HoChong Gilles, NP from the Central Virginia VA Healthcare System, guides viewers through a practical approach to abnormal liver imaging and the challenge of incidental liver lesions. She reviews how to differentiate cystic versus solid liver lesions, outline key risk factors, and interpret enhancement patterns on ultrasound, CT, and MRI to distinguish benign findings—such as simple cysts, hemangiomas, FNH, and hepatic adenomas—from malignant lesions including hepatocellular carcinoma (HCC) and metastatic disease. Designed for APPs and clinicians who frequently encounter unexpected lesions on imaging, this concise overview provides clear strategies for knowing when to reassure, when to monitor, and when to escalate evaluation or referral.
Watch Now
Webcast: Lifestyle Management With Becky Klemme
September 2025
In this educational session, Becky Klemme, NP from Sioux Falls, South Dakota, shares over a decade of hepatology experience to highlight lifestyle management for patients with Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD). Formerly known as NAFLD, MASLD is now the most common chronic liver disease worldwide, closely linked to obesity, type 2 diabetes, hypertension, and cardiovascular disease. Through a detailed patient case, Becky explains how to evaluate MASLD using labs, imaging, and non-invasive tests like FIB-4 and FibroScan, and how to distinguish between simple steatosis, steatohepatitis (MASH), and advanced fibrosis. She outlines practical strategies for dietary changes, exercise, weight loss goals, and metabolic risk reduction—all while keeping patient-centered, culturally sensitive care in mind. Viewers will also learn about the pathogenesis of MASLD and MASH, the role of genetics and lifestyle, and evidence-based approaches such as the Mediterranean diet, structured physical activity, behavioral counseling, and the 5A framework for patient engagement. With obesity and diabetes on the rise, early recognition and proactive lifestyle intervention are essential to preventing progression to cirrhosis, liver failure, or hepatocellular carcinoma (HCC). If you are a hepatology provider, APP, or clinician managing patients with fatty liver disease, this session offers actionable insights and patient care strategies you can use in practice.
Watch Now
Live From GHAPP National: Abnormal Liver Chemistry Workup
November 2025
In this session, Jeremy Davis, ACNP from Shreveport, Louisiana, breaks down a practical, step-by-step approach to evaluating abnormal liver chemistries. Using a real patient case, he reviews how to interpret ALT, AST, ALP, bilirubin, MCV, and GGT patterns; when to suspect hepatocellular, cholestatic, or mixed injury; and how to build an efficient differential using history, medications, alcohol assessment, and key labs (viral hepatitis panel, autoimmune markers, iron studies, Wilson disease testing, alpha-1 antitrypsin phenotype). He also highlights the role of ultrasound, MRCP, non-invasive fibrosis tests (FIB-4, ELF, VCTE), and when biopsy is needed. A practical, clinic-ready guide for APPs and clinicians assessing elevated liver enzymes and differentiating MASLD, alcohol-related disease, DILI, and other common etiologies.
Watch Now
Webcast: MASLD Pharmacotherapy With Lisa Richards
August 2025
Join Lisa Richards from UC San Diego Health, for a comprehensive overview of MASLD Pharmacotherapy as part of the GHAPP MASLD Community Network, proudly sponsored by Madrigal Pharmaceuticals. This educational session explores the evolving treatment landscape for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and MASH (Metabolic Dysfunction-Associated Steatohepatitis), including the shift from exclusive reliance on lifestyle interventions and comorbidity optimization to the introduction of targeted pharmacologic therapies. Lisa reviews the role of GLP-1 receptor agonists, such as semaglutide, and the ESSENCE trial results demonstrating significant improvements in MASH and liver fibrosis. She also outlines the clinical considerations and limitations of legacy treatments like vitamin E and pioglitazone, based on data from the PIVENS trial. The highlight of the session is a detailed exploration of resmetirom (Rezdiffra)—the first FDA-approved therapy for non-cirrhotic NASH with moderate to advanced fibrosis (F2–F3). Lisa reviews key findings from the MAESTRO-NASH trial, including improvements in fibrosis and MASH resolution, and discusses real-world implementation strategies, including non-invasive monitoring tools (FibroScan, ELF, MRI-PDFF), statin dose adjustments, and managing drug–drug interactions. This session equips hepatology and GI providers with the tools to personalize MASH care, navigate insurance and safety considerations, and deliver cutting-edge, evidence-based treatment to patients with MASLD.
Watch Now
Webcast: MASLD Pharmacotherapy With Cheryl Walsh
October 2025
In this talk, Cheryl Walsh, ACNP-C, reviews modern pharmacotherapy for MASLD/MASH—from foundational lifestyle/weight-loss strategies and GLP-1 receptor agonists to legacy options (vitamin E, pioglitazone) and the FDA-approved resmetirom with practical tips on dosing, monitoring, and drug–drug interactions (e.g., statins, procedure planning). She explains how to triage candidates, set realistic diet/exercise goals, and tailor guidance culturally, while outlining safety considerations (GI adverse effects, anesthesia risk) and follow-up with non-invasive tests. Presented via the GHAPP MASLD Community Network with support from Madrigal Pharmaceuticals, this session equips APPs to slow fibrosis progression and improve outcomes.
Watch Now
Webcast: MASLD vs MetALD With Patrick Horne
September 2025
In this case-based session from the GHAPP MASLD Community Network, Patrick Horne, NP explains how to differentiate metabolic dysfunction–associated steatotic liver disease (MASLD) from metabolic dysfunction plus alcohol-associated liver disease (MetALD). Through the story of a 52-year-old patient with F3 fibrosis and severe steatosis, he reviews the modern SLD framework, metabolic risk factors (e.g., BMI, PCOS, hypertension, hyperlipidemia), and how alcohol intake interacts with insulin resistance, the gut microbiome, and hepatic lipid handling to accelerate inflammation and fibrosis. Patrick demonstrates practical tools—clear “standard drink” counseling, thorough history, AUDIT-C screening, and objective biomarkers like PEth—to uncover under-reported alcohol use and classify patients on the MASLD–MetALD–ALD spectrum. Management takeaways include Mediterranean-style nutrition, exercise and weight-loss targets, consideration of pharmacologic options in advanced fibrosis, firm guidance on alcohol cessation, and nuanced discussion of HCC surveillance in F3 disease. Ideal for APPs and hepatology clinicians, this talk delivers actionable algorithms, definitions, and trial-readiness considerations to standardize MetALD assessment and improve outcomes in steatotic liver disease.
Watch Now
Webcast: Comparing F3 and F4 Fibrosis With Allysa Saggese
September 2025
In this session from the MASLD/MASH Community Network, Allysa Saggese, NP from Weill Cornell Medicine in New York, explores the critical differences between F3 and F4 fibrosis through two detailed case studies. Accurate staging is essential in fatty liver disease management, as it directly impacts treatment decisions, eligibility for FDA-approved therapies like resmetirom, and the need for hepatocellular carcinoma (HCC) surveillance. Allysa explains how non-invasive tests such as FIB-4, FibroScan, ELF, CAP, and MRI elastography compare, when to consider a liver biopsy, and how to interpret discordant results. She also discusses treatment pathways, the role of GLP-1 receptor agonists, lifestyle modification, and monitoring strategies for patients with advanced fibrosis versus cirrhosis. This practical overview provides clinicians with a clear framework to distinguish between F3 and F4, ensuring patients receive timely interventions, surveillance, and education to improve long-term outcomes in MASLD/MASH.
Watch Now
Webcast: Non-Invasive Testing With Sherona Bau
July 2025
In this engaging and highly informative GHAPP MASLD Community Network session, Sherona Bau, NP, walks attendees through a practical overview of non-invasive testing (NIT) for evaluating liver health in patients with MASLD (Metabolic dysfunction-associated steatotic liver disease) and MASH (Metabolic dysfunction-associated steatohepatitis). Drawing on real-world clinical experience, Sherona explains why non-invasive testing is essential for identifying fibrosis risk in a population where liver steatosis is prevalent in up to 30% of U.S. adults. Through the case of a 65-year-old Hispanic male named Albert, Sherona demonstrates how to interpret and apply tools such as FIB-4, FibroScan (VCTE and CAP score), ELF (Enhanced Liver Fibrosis) test, and MR Elastography (MRE). She highlights their respective strengths, limitations, clinical cut-offs, and insurance-related considerations. The session also covers when to order tests, how to assess data quality (e.g., IQR/median ratio in VCTE), and when to escalate care to hepatology or cardiology. Whether you are a primary care provider, endocrinologist, or hepatology specialist, this talk delivers practical algorithms and decision-making pathways for managing MASLD, improving early detection of fibrosis and cirrhosis, and integrating cardiovascular risk assessment into liver care. Sherona also emphasizes the importance of alcohol use history, metabolic syndrome risk factors, and annual NIT follow-up in patients at risk for disease progression.
Watch Now
Webcast: Comparing F3 and F4 Fibrosis With Jessica Crimaldi
August 2025
In this educational session, Jessica Crimaldi, a nurse practitioner at Cleveland Clinic with nearly a decade of experience in gastroenterology and hepatology, walks through real-world cases comparing patients with F3 fibrosis and F4 fibrosis. She reviews how to assess disease severity using non-invasive tests like FIB-4, FibroScan, CAP scores, and ELF tests, and explains how clinical findings such as platelets, bilirubin, and INR can guide staging. Jessica highlights the differences in management between patients with advanced fibrosis versus cirrhosis, including the role of lifestyle modifications, GLP-1 therapy, statins, blood pressure control, and Resmetirom for eligible F2/F3 patients. She also discusses the importance of HCC surveillance, portal hypertension evaluation, esophageal varices screening, and long-term monitoring in cirrhosis care. This case-based learning approach offers practical insights into fatty liver disease, MASLD/MASH progression, and optimizing patient outcomes through accurate staging and tailored treatment strategies.
Watch Now
Webcast: MASLD vs MetALD With Erin Parkinson
November 2025
Join Erin Parkinson, APRN, FNP-C for a clear, case-based explainer on diagnosing MetALD versus MASLD. Using a typical patient scenario, Erin shows how to interpret FibroScan (kPa/CAP), translate alcohol “servings” into grams, and use PEth and screening tools (e.g., AUDIT-C, lab clues) to objectively quantify alcohol intake. You’ll learn practical next steps—Mediterranean diet, exercise/weight loss, alcohol abstinence, and when F3 fibrosis should prompt HCC screening—plus how to apply standardized criteria so care and clinical trials compare “apples to apples.”
Watch Now